Malignant rhabdoid tumour in an adult kidney: A case report

Okumura,Yoshinaga; Adachi,Yasushi; Shirahase,Toshihiro; Nagashima,Yoji; Tanaka,Yukichi; Taki,Yoji; Watanabe,Jun; Uegaki,Masayuki; Sakatani,Toru; Ikehara,Susumu

doi:10.3892/mco.2019.1848

Malignant rhabdoid tumour in an adult kidney: A case report

Authors:
- Yoshinaga Okumura
- Yasushi Adachi
- Toshihiro Shirahase
- Yoji Nagashima
- Yukichi Tanaka
- Yoji Taki
- Jun Watanabe
- Masayuki Uegaki
- Toru Sakatani
- Susumu Ikehara
View Affiliations

Affiliations: Department of Urology, Toyooka Hospital, Toyooka, Hyogo 668‑8501, Japan, Department of Diagnostic Pathology, Toyooka Hospital, Toyooka, Hyogo 668‑8501, Japan, Department of Surgical Pathology, Tokyo Women's Medical University, Tokyo 162‑8666, Japan, Clinical Research Institute and Department of Pathology, Kanagawa Children's Medical Center, Yokohama, Kanagawa 232‑8555, Japan, Professor Emeritus, Kansai Medical University, Hirakata, Osaka 573‑1010, Japan
Published online on: April 24, 2019 https://doi.org/10.3892/mco.2019.1848
Pages: 55-58

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant rhabdoid tumours (MRTs) in the kidney are rare paediatric tumours that are extremely rare in adults. We herein report the case of an adult patient with a renal MRT. A 79‑year‑old Japanese woman was found to have a tumour sized 63x48 mm in the left kidney, in addition to multiple metastatic bone and lymph node lesions. The needle biopsy specimen obtained from the patient's kidney revealed tumour cells with rhabdoid characteristics: The cells appeared large, round or polygonal, with eccentrically located nuclei and prominent nucleoli. Immunohistochemically, the tumour cells were positive for vimentin, epithelial membrane antigen, CAM 5.2, and p53, and negative for INI1, cytokeratin (CK)7, CK20, α‑methylacyl‑CoA racemase, S100, CD45, renal cell carcinoma marker, anaplastic lymphoma kinase, α‑smooth muscle actin, desmin, MyoD, myogenin, human melanoma black 45 and melan A. Therefore, the tumour was diagnosed as an MRT located in the kidney. Although the patient was treated with axitinib, a tyrosine kinase inhibitor, the renal tumour and its metastatic lesions continued to progress, and the number of metastatic lesions increased. The patient succumbed to the disease 5 months after the first hospital visit. The disease progression was rapid, with a poor prognosis, consistently with previous reports that of MRTs in the adult kidney.

View Figures

View References

1	Vujanić GM, Sandstedt B, Harms D, Boccon-Gibod L and Delemarre JF: Rhabdoid tumour of the kidney: A clinicopathological study of 22 patients from the International Society of Paediatric Oncology (SIOP) nephroblastoma file. Histopathology. 28:333–340. 1996. View Article : Google Scholar : PubMed/NCBI
2	Lowe W, Weiss RM, Todd MB and True LD: Malignant rhabdoid tumor of the kidney in an adult. J Urol. 143:110–112. 1990. View Article : Google Scholar : PubMed/NCBI
3	Zhao G, Na R, Yang Y and Han R: Pure malignant rhabdoid tumor of the left kidney in an adult: A case report and review of the literature. Oncol Lett. 5:1481–1484. 2013. View Article : Google Scholar : PubMed/NCBI
4	Podduturi V, Campa-Thompson MM, Zhou XJ and Guileyardo JM: Malignant rhabdoid tumor of the kidney arising in an adult patient. Proc (Bayl Univ Med Cent). 27:239–241. 2014. View Article : Google Scholar : PubMed/NCBI
5	Rao Q, Xia QY, Shen Q, Shi SS, Tu P, Shi QL and Zhou XJ: Coexistent loss of INI1 and BRG1 expression in a rhabdoid renal cell carcinoma (RCC): Implications for a possible role of SWI/SNF complex in the pathogenesis of RCC. Int J Clin Exp Pathol. 7:1782–1787. 2014.PubMed/NCBI
6	Roberts CW, Galusha SA, McMenamin ME, Fletcher CD and Orkin SH: Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc Natl Acad Sci USA. 97:13796–13800. 2000. View Article : Google Scholar : PubMed/NCBI
7	Roberts CW and Biegel JA: The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biol Ther. 8:412–416. 2009. View Article : Google Scholar : PubMed/NCBI
8	Sigauke E, Rakheja D, Maddox DL, Hladik CL, White CL, Timmons CF and Raisanen J: Absence of expression of SMARCB1/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: An immunohistochemical study with implications for diagnosis. Mod Pathol. 19:717–725. 2006. View Article : Google Scholar : PubMed/NCBI
9	Hornick JL, Dal Cin P and Fletcher CD: Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol. 33:542–550. 2009. View Article : Google Scholar : PubMed/NCBI
10	Elwood H, Chaux A, Schultz L, Illei PB, Baydar DE, Billis A, Sharma R, Argani P, Epstein JI and Netto GJ: Immunohistochemical analysis of SMARCB1/INI-1 expression in collecting duct carcinoma. Urology. 78:474.e1–e5. 2011. View Article : Google Scholar
11	Jo VY and Fletcher CD: Epithelioid malignant peripheral nerve sheath tumor: Clinicopathologic analysis of 63 cases. Am J Surg Pathol. 39:673–682. 2015. View Article : Google Scholar : PubMed/NCBI
12	Schmidt D, Harms D and Zieger G: Malignant rhabdoid tumor of the kidney. Histopathology, ultrastructure and comments on differential diagnosis. Virchows Arch A Pathol Anat Histopathol. 398:101–108. 1982. View Article : Google Scholar : PubMed/NCBI
13	Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P and Bukowski R: Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 23:832–841. 2005. View Article : Google Scholar : PubMed/NCBI
14	Gunnarsson O, Pfanzelter NR, Cohen RB and Keefe SM: Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma. Cancer Manag Res. 7:65–73. 2015. View Article : Google Scholar : PubMed/NCBI
15	Versteege I, Sévenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, Aurias A and Delattre O: Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 394:203–206. 1998. View Article : Google Scholar : PubMed/NCBI
16	Rousseau-Merck MF, Versteege I, Legrand I, Couturier J, Mairal A, Delattre O and Aurias A: hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors. Cancer Res. 59:3152–3156. 1999.PubMed/NCBI
17	Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM and Fogelgren B: Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 59:74–79. 1999.PubMed/NCBI
18	Pinto EM, Hamideh D, Bahrami A, Orr BA, Lin T, Pounds S, Zambetti GP, Pappo AS, Gajjar A, Agnihotri S and Broniscer A: Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous. Acta Neuropathol. 136:315–326. 2018. View Article : Google Scholar : PubMed/NCBI